Actively Recruiting
DISCRN in Rectal Cancer: DISseCting Response to Neoadjuvant Therapy in Rectal Cancer
Led by Memorial Sloan Kettering Cancer Center ยท Updated on 2026-06-02
60
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how people with rectal cancer respond to standard treatments like chemoradiation and chemotherapy before surgery. The purpose is to understand how the body reacts to these treatments and whether testing blood, tissue, and scans can help predict if the cancer improves, worsens, or stays the same after treatment. This study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on participants with invasive adenocarcinoma of the rectum. Participants will receive standard-of-care neoadjuvant therapy, which includes chemoradiation with induction fluoropyrimidine drugs such as capecitabine or 5-FU, followed by plans for consolidative chemotherapy regimens like CAPEOX, FOLFOX, or FOLIRINOX. Standard endoscopy is used as part of the diagnostic testing during treatment. These treatments and procedures are part of the usual care for rectal cancer, monitored closely within this study. During the study, participants will have tests on their blood, tissue, and scans at different times to help researchers observe the cancer's response to treatment. The main outcome measured is clinical response, which will be followed for up to three years. Participants are monitored for safety and treatment effects throughout this period, with all data collected helping to improve understanding of treatment responses in rectal cancer.
CONDITIONS
Brief Title
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older on day of signing informed consent
- Histologically confirmed diagnosis of invasive adenocarcinoma of the rectum with no known mismatch repair deficiency or Her2 amplification
- Eligible for and planning to start standard chemoradiation with induction fluoropyrimidine (capecitabine or 5-FU) based therapy
- Plan for consolidative chemotherapy with CAPEOX, FOLFOX, or FOLIRINOX
- Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception throughout treatment
You will not qualify if you...
- Prior or concurrent malignancy that may interfere with safety or efficacy assessments
- Prior external beam radiation therapy to the pelvis or prostate brachytherapy seed implantation
- Pregnant or breastfeeding patients
- Men or women not using effective contraception
- Contraindication to MR imaging
- Use of blood thinners that prevent endoluminal tumor biopsies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants undergo standard of care endoscopy and other diagnostic tests before starting neoadjuvant therapy.
Visits scheduled according to standard care for assessment of clinical response
Duration - Up to 3 years
Participants are monitored for clinical response and outcomes following neoadjuvant therapy and surgery.
Follow-up visits occurring over several years to assess treatment response
Trial Site Locations
Total: 6 locations
1
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
2
Memorial Sloan Kettering Bergen (Limited protocol activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
3
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
4
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, United States, 10604
Actively Recruiting
5
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
6
Memorial Sloan Kettering Nassau (Limited protocol activities)
Rockville Centre, New York, United States, 11553
Actively Recruiting
Research Team
P
Paul Romesser, MD
A
Andrea Cercek, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here